Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06748222 · ClinicalTrials.gov registry record · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
A Phase 3 study of Breast Cancer and Depression, sponsored by NRG Oncology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
- 20
- Study locations
NCT06748222: Recruiting Phase 3 study of Breast Cancer and Depression, sponsored by NRG Oncology.
NCT06748222 is a Phase 3 study of Breast Cancer and Depression that is actively recruiting participants, run by NRG Oncology. The registered enrollment target is 402 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06748222, a Phase 3 study of Breast Cancer and Depression, is actively recruiting participants, sponsored by NRG Oncology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
- 20
- Study locations
Study Summary
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.
Primary Outcome
The Center for Epidemiologic Studies-Depression (CES-D) score. The score is calculated as the sum of the points for all 10 items. The score range is 0-30 and a score of 10 or greater is considered depressed.
Conditions Studied
Interventions
- BEHAVIORAL Mindfulness (MAPs) Live Online
- BEHAVIORAL Mindfulness (MAPs) Digital App
- BEHAVIORAL Meditation Only Control Group
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- AIS Cancer Center at San Joaquin Community Hospital - Bakersfield
- Marshall Cancer Center - Cameron Park
- Enloe Medical Center - Chico
- UC Irvine Health Cancer Center-Newport - Costa Mesa
- Kaiser Permanente Dublin - Dublin
- Kaiser Permanente-Fremont - Fremont
- Washington Hospital - Fremont
- Kaiser Permanente Fresno Orchard Plaza - Fresno
- Kaiser Permanente-Fresno - Fresno
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- Fremont - Rideout Cancer Center - Marysville
- Kaiser Permanente- Modesto MOB II - Modesto
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente-Oakland - Oakland
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
- Eisenhower Medical Center - Rancho Mirage
- Kaiser Permanente- Marshall Medical Offices - Redwood City
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2025-06-12 |
| Est. Completion | 2030-02-28 |
| Phase | Phase 3 |
What NCT06748222 shows while recruiting
NCT06748222 is an interventional study that assigns participants to a tested intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Mindfulness (MAPs) Live Online is the first listed.
NCT06748222 names 20 study sites across 3 states, led by California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06748222 about?
NCT06748222 is a clinical study titled "E-Mindfulness Approaches for Living After Breast Cancer". NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wil...
What is the current status of trial NCT06748222?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2025-06-12. Estimated completion is 2030-02-28.
What conditions does trial NCT06748222 study?
This clinical trial studies the following conditions: Breast Cancer, Depression.
What interventions are being tested in trial NCT06748222?
The interventions under investigation include: Mindfulness (MAPs) Live Online (BEHAVIORAL), Mindfulness (MAPs) Digital App (BEHAVIORAL), Meditation Only Control Group (BEHAVIORAL).
Who is sponsoring clinical trial NCT06748222?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06748222 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06748222's enrollment target sits among peer trials
402 230th of 1224 higher than 994 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT05647122 · 403 participants · Phase 1
First in Human Study of AZD9592 in Solid Tumors
- NCT05674799 · 403 participants · NA
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI